From compliance to confidence: how pharmaceutical quality management is evolving

Summary 

Framed around four key insights from dsm-firmenich’s customers—this blog explores how moving from reactive compliance to a more proactive, confidence-led approach to quality can support greater confidence, reduced risk, and faster progress from development to delivery—brought to life through Verilege™ principles.

Quality has always been a cornerstone of pharmaceutical manufacturing. But today, the expectations placed on quality systems—which underpin regulatory confidence, operational efficiency, and ultimately patient safety—are becoming more demanding. At the same time, regulatory complexity and broader policy changes—such as the European Union’s (EU) Critical Medicines Act (CMA), which highlights the importance of supply continuity—are adding further pressure. 

As demand intensifies, pharmaceutical quality is no longer viewed as a single function or final checkpoint, but as a connected, end-to-end system—spanning suppliers, processes, documentation, and partnerships across the entire value chain. This shift is reflected in recent conversations with our customers. Our partners are increasingly taking a more proactive approach to quality management to help reduce uncertainty, improve visibility, and enable teams to operate with confidence. Drawing on these perspectives, Ulrike Becker, Associate Director at dsm-firmenich, explores four key insights from our customer interactions—and what they reveal about the evolving role of quality in pharma today.

Insight 1: Quality is built on trust, transparency, and long-term partnerships

Pharmaceutical quality management is often viewed as documentation and inspections—but in reality, it goes much deeper than that. As one customer put it: “Quality doesn’t start with these processes—it starts with relationships and trust.” This reflects a broader shift we’re seeing across the industry. Pharmaceutical companies are increasingly looking beyond transactional supplier models toward partnerships built on transparency, shared responsibility, and long-term alignment. These relationships don’t just improve collaboration—they create the foundation for sustained quality and regulatory confidence.

As Ulrike explains: “Resilience today isn’t just about having multiple suppliers. It’s about working with customers you can rely on - partners who consistently demonstrate GMP compliance, manage changes well, and stay reliable over time. At dsm-firmenich, we focus on building these kinds of relationships by openly and willingly sharing quality and regulatory information, communicating about potential changes as early as possible, and aligning on documentation processes and compliance expectations.”

This change from transactional to strategic quality management highlights that quality is no longer owned by one function or one organization; it’s shared across the value chain. When that shared responsibility is in place, it becomes much easier to maintain consistency, avoid surprises, and support continuity from manufacturer to patient.

Insight 2: Documentation is becoming a strategic priority 

One area that is becoming a growing burden is documentation. Many of our customers have said that the growing volume and complexity of documentation is difficult to manage. From global registrations to lifecycle changes, even small updates—like analytical changes or site adjustments—can create significant workload if information is delayed, unclear, or inconsistent. 

Ulrike continues: “Documentation has become more complex, meaning teams have to manage multiple dossiers across regions, ongoing variations, and rising expectations for traceability and inspection readiness. As such, there is a clear opportunity to improve this experience for customers. We do this by providing not just compliance documents, but structured, consistent, and timely support. This helps our partners gain the clarity and predictability they need to plan ahead, reduce their workload, and prevent potential bottlenecks.”

Insight 3: Strong supplier quality foundations support proactive risk management 

Another theme we consistently hear from customers is the value of identifying and addressing issues early. In pharmaceutical quality, risks rarely begin as major failures. More often, they start as minor issues - slight inconsistencies in documentation, small gaps in filed dossiers and processes, or delays in communicating changes. When these are spotted and managed early, companies can prevent escalation and maintain smoother, more confident audit and inspection outcomes.

Ulrike explains: “What often looks like a small issue at the beginning can become much bigger later on. That’s why we work closely with our customers to ensure early visibility of changes, transparent communication, and robust, inspection-ready documentation, so potential issues are addressed before they have the chance to escalate. This is particularly important because regulators ultimately hold the marketing authorization holder accountable for the entire supply chain. As a result, supplier-related issues don’t stay in isolation. Instead, they can translate directly into inspection observations, delayed approvals, or, in more serious cases, product recalls or supply restrictions. Strong supplier quality foundations - built on transparency, alignment, and proactive communication - are therefore essential to managing risk effectively.”

Insight 4: Proactive quality beats reactive compliance

Many of our customers recognize that reacting to regulatory change is no longer good enough. Instead, they are shifting toward a more proactive quality strategy - one that anticipates challenges rather than responding to them. This approach reduces uncertainty and keeps companies ahead of evolving expectations. 

As Ulrike explains: “Staying ahead doesn’t mean reacting faster - it means thinking about what’s next. It’s about understanding regulatory trends, assessing risks early, and preparing before something becomes an issue. At dsm-firmenich, we support this by working closely with our suppliers and customers to ensure alignment on upcoming changes and their impact—so there are fewer surprises and more control. 

In practice, this involves:

• Continuous monitoring of regulatory and inspection trends.
• Cross-functional alignment across quality, regulatory, and supply chain teams.
• Early assessment of how changes may impact dossiers and compliance.

“The result is a more controlled, predictable environment—where teams can reduce rework, streamline processes, and approach inspections with greater confidence. Ultimately, proactive quality isn’t just about reducing risk. It’s about enabling more informed decision-making.”

What these insights mean in practice 

As expectations continue to rise across the pharmaceutical market, companies are looking for partners who can go beyond supplying ingredients to actively supporting their quality and regulatory processes. This is where Verilege™ can support. Our active pharmaceutical ingredients (API) portfolio is powered by a suite of expert services—including quality, regulatory, sustainability, and supply chain services—and superior customer care. Through Verilege™, we deliver consistent, high-quality APIs across our global network through: 

• GMP-certified facilities adhering to the highest manufacturing standards.
• Robust quality control processes.
• ICHQ7 compliance for reliable pharmaceutical-grade ingredients.
• Continuous investments, with regular inspections by various authorities (such as the FDA, MHRA, swissmedic, ANSM, and the PMDA).

By adopting a proactive mindset, focusing on end-to-end documentation lifecycle support, and working closely with our customers’ quality and regulatory teams, we provide greater clarity, predictability, and confidence. This helps reduce uncertainty so that our pharmaceutical partners can focus on developing and delivering medicines to patients.